ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

NCT05358808 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.

Conditions

Interventions

Sponsor

TC Biopharm